Date: February 19, 2018
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is primarily a bio-pharmaceuticals company with a focus towards innovative antibiotic medicines. Its most well-known and innovative product is a tetracycline antibiotic called Omadacycline.
Omadacycline has broad spectrum activity and is effective in both an IV and oral form making it ideal for resistant infections. First new class of antibiotics in 30 years.
Omadacycline has been achieving success along the FDA approval process and had positive phase III results in ABSSSI and has recently had a phase III positive result for CABP as well. This current streak of positives for Paratek is a good indication that the company can further develop its drug Omadacycline for other similar diseases as well.
The most recent positive for Paratek is the awarding of Qualified Infectious Disease Product (QIDP) status for curing uncomplicated urinary tract infection.
Omadacycline has received a breakthrough designation from FDA which mean it is a drug for unmet medical which increase its chances of success tremendously.
PRK Just finished it rolling NDA submission and a PDUFA date might be set as soon as in Q3 2018.
It just raised 50M cash via secondary offering thus near term cash issue in resolved.
Considering its product, it valuation, and the cash position it is a probable take-over target by big pharma.